Tempus AI Inc. reported second-quarter 2025 revenue of $314.6 million, exceeding the roughly $297 million consensus estimate and rising almost 90 % from a year earlier. Adjusted earnings per share narrowed to a loss of 22 cents, outperforming the expected 24-cent loss, as the precision-medicine company expanded its genomic testing and data analytics operations. Gross profit climbed 158 % to $195 million, while adjusted EBITDA improved to a loss of $5.6 million from a $31.2 million deficit a year ago. The company completed about 212,000 next-generation sequencing tests during the quarter, driving a 115 % increase in genomics revenue to $241.8 million; data and services revenue rose 36 % to $72.8 million. Net loss narrowed sharply to $42.8 million, and cash on hand grew to $293 million. Citing faster-than-expected volume growth and improving margins, management lifted its full-year 2025 revenue outlook to roughly $1.26 billion from $1.25 billion and reaffirmed its goal of achieving a positive $5 million in adjusted EBITDA. The stock gained between 9 % and 12 % in pre-market trading, with analysts pointing to momentum from the company’s AI-driven oncology platform and a recently announced $200 million collaboration with AstraZeneca.